V900323
Hydroxyurea
Vetec™, reagent grade, ≥98%
Synonym(s):
Hydroxycarbamide
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
Linear Formula:
NH2CONHOH
CAS Number:
Molecular Weight:
76.05
Beilstein:
1741548
EC Number:
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
grade
reagent grade
product line
Vetec™
Assay
≥98%
storage temp.
2-8°C
SMILES string
NC(=O)NO
InChI
1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
InChI key
VSNHCAURESNICA-UHFFFAOYSA-N
Gene Information
human ... RRM1(6240), RRM2(6241), RRM2B(50484)
Looking for similar products? Visit Product Comparison Guide
Biochem/physiol Actions
Anti-neoplastic. Inactivates ribonucleoside reductase by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. This blocks the synthesis of deoxynucleotides, which inhibits DNA synthesis and induces synchronization or cell death in S-phase.
Legal Information
Vetec is a trademark of Merck KGaA, Darmstadt, Germany
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Muta. 1B - Repr. 2
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Deepa Manwani et al.
Blood, 122(24), 3892-3898 (2013-09-21)
Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted
Guido Finazzi et al.
British journal of haematology, 161(5), 688-694 (2013-04-12)
Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has shown significant activity with good tolerability in patients with chronic myeloproliferative neoplasms (MPN). In this multicentre, open-label, phase II study, 44 patients with polycythaemia
Winfred C Wang et al.
Pediatrics, 132(4), 677-683 (2013-09-04)
In the BABY HUG trial, young children with sickle cell anemia randomized to receive hydroxyurea had fewer episodes of pain, hospitalization, and transfusions. With anticipated broader use of hydroxyurea in this population, we sought to estimate medical costs of care
Suchitra Natarajan et al.
Neoplasia (New York, N.Y.), 15(3), 263-280 (2013-03-13)
The non-histone chromatin binding protein high mobility group AT-hook 2 (HMGA2) is expressed in stem cells and many cancer cells, including tumor initiating cells, but not translated in normal human somatic cells. The presence of HMGA2 is correlated with advanced
A Tefferi et al.
Leukemia, 28(12), 2300-2303 (2014-05-06)
The impact of calreticulin (CALR) mutations on long-term survival in essential thrombocythemia (ET) was examined in 299 patients whose diagnosis predated 2006. Mutational frequencies were 53% for Janus kinase 2 (JAK2), 32% for CALR and 3% for MPL; the remaining
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service